Status:
COMPLETED
Triple Versus Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation
Lead Sponsor:
Shenyang Northern Hospital
Conditions:
Acute Coronary Syndrome
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Cilostazol is an kind of oral antiplatelet agent with a rapid onset of action that selectively inhibits phosphodiesterase III, a mechanism different from adenosine diphosphate (ADP) receptor antagonis...
Eligibility Criteria
Inclusion
- Diagnosed with ACS Undergoing coronary stent implantation
- Between ages of above 18 Years and bellow 80 Years.
- Presence of one or several stenosis in native coronary arteries requiring PCI.
- Willing and able to sign informed consent.
Exclusion
- A history of bleeding diathesis.
- New York Heart Association functional class IV.
- Prior PCI or coronary bypass grafting \< 3 months.
- Contraindications to clopidogrel and aspirin (White blood cells counts \< 4×109/L or platelet counts \<100 g.l-1 ;creatinine clearance \<25 ml • min-1 ;active liver disease).
- Use of glycoprotein IIb/IIIa inhibitors before PCI.
- Preparing to undergo CABG
- Taken clopidogrel or cilostazol recently
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
End Date :
February 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00404716
Start Date
December 1 2004
End Date
February 1 2007
Last Update
November 29 2006
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.